low dose dexamethasone

Related by string. * lower . Lows . LOWER . lows . LOW : 4 KEY Low . Lower Ninth Ward . Low Carbon . low enriched uranium . low carb diet / DO Se . Doses . DOSE . DOSES : mg kg dose . tolerated dose MTD . label dose escalation . dose escalation study / Dexamethasone : corticosteroid dexamethasone . lenalidomide dexamethasone . lenalidomide dexamethasone treatment . thalidomide dexamethasone * *

Related by context. All words. (Click for frequent words.) 70 XELOX 69 plus dexamethasone 69 carboplatin paclitaxel 69 dose dexamethasone 68 chlorambucil 68 FOLFOX4 68 FOLFOX 67 galiximab 67 pegylated liposomal doxorubicin 66 dose cytarabine 66 pomalidomide 66 dacarbazine 66 interferon alfa 2a 65 chemoradiotherapy 65 mg qd 65 bevacizumab 65 FOLFIRI 65 relapsed MM 65 5-FU/LV 65 lenalidomide 65 ritonavir boosted atazanavir 65 Peg IFN 64 dasatinib 64 pegylated interferon alfa 2b 64 pemetrexed 64 fludarabine 64 bortezomib 64 Doxil ® 64 unfractionated heparin UFH 64 decitabine 64 mapatumumab 64 Flu Cy 64 standard chemotherapy regimen 64 Folfox 64 telaprevir dosed 64 gemcitabine carboplatin 64 plus prednisone 63 postoperative chemotherapy 63 docetaxel chemotherapy 63 bendamustine 63 peginterferon alfa 2a 63 ABVD 63 mycophenolate mofetil 63 fluorouracil leucovorin 63 chemoradiation therapy 63 sorafenib Nexavar ® 63 low dose cytarabine 63 docetaxel 63 doxorubicin cyclophosphamide 63 locoregional 63 mg m² 63 gemcitabine chemotherapy 63 VELCADE melphalan 63 neoadjuvant 63 pertuzumab 63 idarubicin 63 comparator arm 63 Pegasys ® 63 gemcitabine 63 adriamycin 63 nodular partial response 63 infliximab monotherapy 63 HER2 positive metastatic breast 63 lopinavir r 63 melphalan prednisone 63 temsirolimus 63 Taxotere ® 63 CLL SLL 63 mRCC 63 dacarbazine DTIC 63 mg/m2 dose 62 nab paclitaxel 62 daunorubicin 62 metastatic renal cell carcinoma 62 Ceplene/IL-2 62 placebo dexamethasone 62 atazanavir ritonavir 62 relapsed refractory multiple myeloma 62 pegylated interferon alfa 2a 62 mitoxantrone 62 estramustine 62 erlotinib 62 tamsulosin 62 trastuzumab 62 ACTEMRA TM 62 sunitinib 62 azathioprine 62 cetuximab 62 azacitidine 62 topotecan 62 chemoradiation 62 Fludarabine 62 8mg/kg 62 temozolomide 62 nilotinib 62 methotrexate MTX 62 docetaxel Taxotere R 62 ABC/3TC 62 fluorouracil 62 capecitabine 62 CHOP chemotherapy 62 LPV r 62 CIMZIA TM 61 oral rivaroxaban 61 iniparib 61 heavily pretreated patients 61 Fludara 61 mcg albinterferon alfa 2b 61 capecitabine Xeloda 61 etanercept 61 azacytidine 61 dexamethasone 61 PREZISTA ritonavir 61 Capecitabine 61 DOXIL 61 adalimumab 61 rituximab 61 darunavir ritonavir 61 plus gemcitabine 61 imipenem 61 dose melphalan 61 sirolimus eluting stent 61 evaluable patients 61 REVLIMID 61 TAXOTERE R 61 #mg BID [001] 61 fulvestrant 61 ritonavir boosted 61 peginterferon alpha 2a 61 abacavir lamivudine 61 CR nPR 61 pegylated interferon alfa 61 epirubicin cyclophosphamide 61 efavirenz EFV 61 cisplatin gemcitabine 61 free survival PFS 61 FOLPI 61 sorafenib 61 gemcitabine Gemzar 61 tocilizumab 61 HBeAg negative patients 61 Peginterferon 61 carboplatin 61 mcg QD 61 mg QD 61 abciximab 61 tiotropium 60 KRAS mutations occur 60 imatinib 60 bortezomib Velcade R 60 cisplatin chemotherapy 60 Tarceva TM 60 monotherapy 60 temozolomide TMZ 60 alfa 2a 60 active comparator 60 chemotherapy cisplatin 60 dexamethasone Decadron 60 plus ribavirin 60 PREZISTA r 60 oral diclofenac 60 metastatic GIST 60 Torisel 60 irbesartan 60 glatiramer acetate 60 fluticasone salmeterol 60 CANCIDAS 60 follicular NHL 60 refractory NSCLC 60 lopinavir r arm 60 patients evaluable 60 adecatumumab 60 Navelbine 60 mcg kg 60 bevacizumab Avastin ® 60 eplerenone 60 CRu 60 docetaxel Taxotere 60 BEACOPP 60 cyclophosphamide 60 fluconazole 60 sorafenib Nexavar 60 vinorelbine 60 TORISEL 60 tolvaptan 60 febrile neutropenia 60 metastatic hormone refractory 60 APTIVUS r 60 ara C 60 cyclophosphamide doxorubicin vincristine 60 vandetanib 60 adjunctive placebo 60 APTIVUS 60 idraparinux 60 mg BID 60 FluCAM 60 mitomycin 60 doripenem 60 erlotinib Tarceva ® 60 liposomal doxorubicin 60 anthracycline taxane 60 cabazitaxel 60 ALT normalization 60 ribavirin RBV 60 oral Xeloda 60 cytarabine daunorubicin 60 enzastaurin 60 amoxicillin clavulanate 60 interferon alfa 2b 60 FOLFOX6 60 oblimersen 60 biologic DMARD 60 imatinib therapy 60 oral clodronate 60 clodronate 60 oral levofloxacin 60 Lenalidomide 60 gemcitabine cisplatin 60 methotrexate monotherapy 60 5FU 60 biochemical relapse 60 Taxotere R 60 PegIFN RBV 60 imatinib resistant 59 neoadjuvant chemotherapy 59 afatinib 59 CIMZIA ™ 59 peginterferon alfa 2b 59 relapsed multiple myeloma 59 partial remissions 59 5 FU leucovorin 59 salmeterol fluticasone 59 metastatic castration resistant 59 refractory chronic lymphocytic 59 Pemetrexed 59 stage IIIb IV 59 pimecrolimus 59 plus methotrexate 59 gp# vaccine 59 Bevacizumab 59 goserelin 59 bicalutamide 59 chemotherapy gemcitabine 59 DMARDs 59 Gemzar ® 59 NMIBC 59 mCRC patients 59 cisplatin vinorelbine 59 tenofovir emtricitabine 59 #.#mg/dL 59 paricalcitol 59 fluoropyrimidine 59 dasatinib Sprycel ® 59 lamivudine 59 adjunctive ABILIFY 59 6 mercaptopurine 59 viral kinetics 59 cytarabine 59 FOLFIRI alone 59 Paraplatin ® 59 Fulvestrant 59 receiving VICTRELIS 59 sorafenib tablets 59 oxaliplatin 59 neoadjuvant treatment 59 Peginterferon Alfa 2a 59 weekly subcutaneous injections 59 elotuzumab 59 conventional DMARDs 59 IFN beta 59 KRAS wild 59 leukemia AML 59 bosentan 59 doxorubicin HCl liposome injection 59 DMARD therapy 59 thymalfasin 59 DMARD 59 tirofiban 59 noninferior 59 piperacillin tazobactam 59 achieved ACR# 59 REYATAZ r arm 59 nadolol 59 cisplatin 59 certolizumab 59 dose regimens 59 Xelox 59 Hazard Ratio 59 dose atorvastatin 59 relapsed refractory 59 veltuzumab 59 posaconazole 59 multicentre randomized 59 ACR# response 59 TACE 59 protease inhibitor PI 59 EBRT 59 infusional 5-FU/LV 59 gefitinib 59 4mg/kg 59 HCV RESPOND 2 59 tapentadol ER 59 tigecycline 59 divalproex sodium 59 mg kg dose 59 DMARDS 59 Platinol ® cisplatin 59 irinotecan doxorubicin oxaliplatin paclitaxel 59 adjuvant tamoxifen 59 metastatic RCC 59 Teriflunomide 59 daily Infergen 59 trastuzumab Herceptin R 59 5 fluorouracil 59 TAXUS Liberte Long 59 IFN α 59 mg BID dose 59 ELOXATIN 59 alpha 2a 59 ZACTIMA 59 refractory AML 59 standard chemotherapy regimens 58 pharmacodynamic properties 58 infliximab 58 docetaxel prednisone 58 Imprime PGG 58 Pegylated Interferon 58 Targretin 58 adjuvant radiation 58 zonisamide SR 58 metastatic malignant 58 TAXUS Express Stent 58 pegylated interferon alpha 58 Pegasys plus Copegus 58 metastatic colorectal carcinoma 58 NPH insulin 58 CIMZIA TM certolizumab pegol 58 peginterferon 58 lenalidomide dexamethasone 58 iniparib BSI 58 desvenlafaxine succinate 58 lenalidomide Revlimid R 58 neoadjuvant therapy 58 Free Survival PFS 58 oxycodone CR 58 flutamide 58 bupropion SR 58 PEG IFN 58 systemic corticosteroid 58 splenectomized 58 sustained virologic response 58 cytotoxic chemotherapy 58 adjuvant radiotherapy 58 unfractionated heparin 58 EURIDIS 58 paclitaxel chemotherapy 58 lumbar spine BMD 58 follicular lymphoma FL 58 metastatic HRPC 58 PREZISTA rtv 58 Xeloda ® 58 docetaxel Taxotere ® 58 interferon alfa 58 dabigatran etexilate 58 Platinol ® 58 talabostat 58 pamidronate 58 chemotherapy docetaxel 58 LEXIVA r 58 DAPT 58 platinum refractory 58 Ibritumomab Tiuxetan 58 oral chemotherapeutic agent 58 HBeAg seroconversion 58 pyrazinamide 58 FOLFOX4 alone 58 sunitinib malate 58 nondiabetic patients 58 BARACLUDE ® 58 neurologic progression 58 MGd 58 rFVIIa 58 boosted protease inhibitor 58 metformin sulfonylurea 58 CsA 58 dose interleukin 58 evaluable subjects 58 pCR 58 COPEGUS 58 PEGINTRON TM 58 Lupuzor ™ 58 -#.# log# 58 Degarelix 58 R# #mg BID 58 NRTIs 58 paclitaxel Taxol ® 58 virologic response 58 resected pancreatic cancer 58 gefitinib Iressa 58 hematologic toxicity 58 zoledronic acid 58 Subgroup analysis 58 degarelix 58 paclitaxel carboplatin 58 K ras mutations 58 median PFS 58 timolol 58 bevacizumab Avastin R 58 crizotinib PF # 58 olmesartan 58 unresectable stage 58 antitumor activity 58 Bezielle 58 nicardipine 58 carboplatin chemotherapy 58 mutated KRAS 58 otamixaban 58 squamous histology 58 CA4P 58 mitoxantrone chemotherapy 58 neutrophil counts 58 RLAI 58 Carboplatin 58 follicular lymphomas 58 steroid dexamethasone 58 Bortezomib 58 #Gy 58 iobenguane 58 octreotide LAR 58 % CI #.#-#.# [007] 58 titrated glipizide 58 recurrent glioblastoma multiforme 58 prucalopride 58 TNF antagonists 58 complete cytogenetic response 58 GnRH agonist 58 mTOR inhibitors 57 preoperative chemotherapy 57 evaluating tivozanib 57 Myelodysplastic Syndrome MDS 57 #mg/m# [002] 57 lapatinib Tykerb 57 Navelbine ® 57 zalutumumab 57 huN# DM1 57 anti TNF 57 melphalan 57 TTF Therapy 57 CRp 57 pan HDAC inhibitor 57 biliary tract cancer 57 #mg/m# [001] 57 androgen suppression 57 chlorthalidone 57 ertapenem 57 DAS# remission 57 dose clopidogrel 57 mg/m2/day 57 CR CRu 57 folinic acid 57 metastatic lung cancer 57 leukemia CLL 57 remission CR 57 relapsed myeloma 57 bivalirudin monotherapy 57 Ribavirin 57 ELACYT 57 eribulin mesylate 57 eptifibatide 57 FUSILEV enhances 57 trastuzumab Herceptin ® 57 receiving SIMPONI 57 axitinib 57 peginterferon alfa 57 capecitabine Xeloda R 57 sulfasalazine 57 bivalirudin 57 bleomycin 57 stage IIIB 57 alpha 2b 57 doxazosin 57 NATRECOR ® 57 invasive candidiasis 57 methotrexate 57 #mg doses [002] 57 prostate cancer HRPC 57 nitazoxanide 57 heavily pretreated 57 candesartan cilexetil 57 subcutaneously administered 57 IFN alpha 57 FOSRENOL ® 57 mg ustekinumab 57 angiographic outcomes 57 Doxil 57 mitoxantrone plus 57 mCi kg 57 REYATAZ r 57 allogeneic SCT 57 etoposide 57 Aflibercept 57 apremilast 57 pioglitazone 57 microbiological eradication 57 ATACAND 57 mcg BID 57 saline placebo 57 locoregional recurrence 57 thalidomide Thalomid 57 recurrent malignant glioma 57 PROMACTA 57 cytogenetic responses 57 rizatriptan 57 doxorubicin docetaxel 57 paclitaxel cisplatin 57 imatinib Gleevec 57 tiotropium bromide 57 atorvastatin #mg 57 ALT elevation 57 PREZISTA r arm 57 anastrazole 57 complete remissions 57 multicenter randomized placebo controlled 57 irinotecan chemotherapy 57 TNF antagonist 57 serum cortisol 57 AZILECT 57 systemic ALCL 57 pimecrolimus cream 57 zoledronate 57 recurrent GBM 57 Pharmacokinetics PK 57 dose ritonavir 57 fluvastatin 57 REMICADE monotherapy 57 evaluable 57 YERVOY 57 achieved statistical significance 57 Gemcitabine 57 baseline LDH 57 Combination therapy 57 chemotherapy FOLFOX 57 pegylated interferon 57 PegIFN 57 sunitinib Sutent ® 57 grade cervical intraepithelial 57 3TC lamivudine Epivir 57 cyclophosphamide chemotherapy 57 remission induction 57 plus prednisone prednisolone 57 indapamide 57 HuMax EGFr 57 Jevtana 57 amprenavir 57 Aptivus ® 57 moderate renal impairment 57 pharmacokinetics PK 57 μmol L 57 Elitek 57 PEGylated Fab fragment 57 pegylated liposomal doxorubicin PLD 57 elacytarabine 57 lispro 57 % Confidence Interval 57 Kaplan Meier analysis 57 cardiac toxicity 57 interferon ribavirin 57 double blinded randomized 57 mycophenolate mofetil MMF 57 paclitaxel eluting stents 57 INCB# [003] 57 mcg dose 57 Engerix B 57 ARIMIDEX 57 interferon beta 1a 57 resectable 57 virologic 57 metformin monotherapy 57 radiochemotherapy 57 insulin detemir 57 argatroban 57 dose escalation 57 DLTs 57 HBeAg 57 intravenous bisphosphonates 57 Kaplan Meier 57 FOLFOX6 chemotherapy regimen 57 ug kg 57 oral allopurinol 57 AEGR 57 AVASTIN 57 Taxotere 57 epirubicin 57 adalimumab Humira 57 Copegus ribavirin 57 Fluorouracil 57 adjuvant therapy 57 PEG interferon 57 pT3 57 Gemzar gemcitabine 57 EGFR mutation positive 56 vincristine doxorubicin 56 concurrent chemoradiation 56 postmenopausal osteoporotic women 56 aprepitant 56 μg dose 56 Vidaza ® 56 trabectedin 56 Toxicities 56 BENICAR HCT 56 CYPHER Stent 56 temsirolimus Torisel ® 56 Hodgkin lymphoma NHL 56 PEGASYS ® 56 sustained virological response 56 prospectively randomized 56 enalapril 56 hormone refractory metastatic prostate 56 teriflunomide 56 xenograft models 56 Diffuse Large B 56 Traficet EN 56 haematologic 56 dose cohorts 56 pain palliation 56 sulphonylurea 56 mg TID 56 #mg/day [001] 56 androgen deprivation 56 Pegylated Liposomal Doxorubicin 56 morphometric vertebral fractures 56 iodixanol 56 SPRYCEL ® 56 adefovir 56 DEB# 56 VFEND 56 virological failure 56 ug dose 56 evaluating REVLIMID 56 paclitaxel Taxol 56 aflibercept VEGF Trap 56 recurrent genital herpes 56 Irinotecan 56 stavudine d4T 56 mg RDEA# 56 zidovudine lamivudine 56 sorafenib Nexavar R 56 splenectomized patients 56 #mg/kg [002] 56 radiotherapy RT 56 custirsen 56 prior chemotherapy regimens 56 linezolid 56 HIV HCV coinfected 56 Median PFS 56 cilengitide 56 S/GSK# 56 discontinuations due 56 STELARA 56 microgram kg 56 cyclophosphamide methotrexate 56 adjuvant chemotherapy 56 metastatic malignant melanoma 56 entecavir 56 doxorubicin 56 EGFR TKI 56 Herceptin trastuzumab 56 dasatinib Sprycel 56 microg 56 d4T stavudine Zerit 56 Xanafide 56 RECIST criteria 56 IFN alfa 56 FOLFOX chemotherapy 56 Femara letrozole 56 cyclophosphamide Cytoxan 56 randomized multicenter Phase III 56 FOSRENOL R 56 lymphocytosis 56 locoregional disease 56 potent CYP#A# inhibitors 56 TLUS 56 baminercept 56 FASLODEX 56 Tolerability 56 refractory multiple myeloma 56 adjuvant trastuzumab 56 vidofludimus 56 pancreatic adenocarcinoma 56 NCCTG N# 56 DFMO 56 gemcitabine Gemzar ® 56 Secondary endpoints 56 fondaparinux 56 neutropaenia 56 cetuximab Erbitux R 56 antiangiogenic therapy 56 antitumor effect 56 overlapping toxicities 56 mg/m2 56 levetiracetam 56 Hazard Ratio HR 56 trabedersen 56 Amrubicin 56 Alocrest 56 prednisone prednisolone 56 anthracycline 56 CoFactor 56 femoral neck BMD 56 MAGE A3 ASCI 56 rFSH 56 TMC# r 56 cytogenetic response 56 serum phosphorus 56 antiretroviral naïve 56 pharmacodynamic profiles 56 metastatic CRC 56 daily subcutaneous injections 56 pegylated interferon peg IFN 56 ULORIC 56 KRAS mutant tumors 56 HBeAg negative 56 GOUT 56 grade gliomas 56 paclitaxel poliglumex 56 p = NS 56 pyridostigmine 56 recurrent glioblastoma 56 omalizumab 56 bortezomib Velcade 56 everolimus eluting stents 56 autologous stem cell 56 neratinib 56 azilsartan medoxomil 56 luteinizing hormone releasing 56 ibandronate 56 Partial Responses 56 Perforomist Inhalation Solution 56 Taxus Stent 56 voriconazole 56 randomized multicenter trial 56 analgesic efficacy 56 continuous intravenous infusion 56 Darusentan 56 lymphopenia 56 angiotensin converting enzyme inhibitor 56 ALT flares 56 enfuvirtide 56 alefacept 56 mg/m2 administered 56 TELCYTA 56 BRAF inhibitor 56 Trastuzumab 56 ARB telmisartan 56 YONDELIS 56 BRIM2 56 methotrexate therapy 56 L PPDS 56 herpetic keratitis 56 tipranavir r 56 TAXOTERE ® 56 hepatic metastases 56 EBMT criteria 56 pharmacokinetic characteristics 56 chemoembolization 56 Azedra 56 pegylated interferon alpha 2a 56 strontium ranelate 56 EOquin TM 56 AGILECT R 56 caspofungin 56 platelet inhibitor 56 sertraline 56 PASI scores 56 oral FTY# 56 Pegasys R 56 resectable pancreatic cancer 56 AZT zidovudine Retrovir 56 alpha blocker 56 curative resection 56 tolerability pharmacokinetics 56 Betaferon ® 56 ceftazidime 56 histologic subtype 56 visilizumab 56 levofloxacin 56 Omacetaxine 56 alkylating agent 56 liver histology 56 aldosterone antagonist 56 anti leukemic 56 p ≤ 56 RRMS patients 56 fluticasone propionate 56 ZOLINZA 56 dose cohort 56 HBeAg positive patients 56 esophageal candidiasis 56 HCV SPRINT 56 angiotensin receptor blocker ARB 56 serum urate 56 SCH # 56 amphotericin B 56 distant metastasis 56 randomized Phase III 56 MabCampath 56 neutropenia dehydration dyspnea 56 moxifloxacin 56 Erlotinib 56 relapsed CLL 56 XIENCE V PROMUS Stent 56 investigational protease inhibitor 56 NATRECOR R 56 oxaliplatin Eloxatin 56 serum HBV DNA 55 vorinostat 55 PSA nadir 55 treatment naïve genotype 55 #μg [001] 55 previously untreated follicular 55 leuprorelin 55 Ophena TM 55 lamivudine monotherapy 55 hydroxychloroquine 55 rosuvastatin #mg 55 insulin glargine 55 Copegus ® 55 registrational Phase 55 mg/m2 IV 55 milatuzumab 55 β blockers 55 letrozole Femara 55 Panzem R NCD 55 Azacitidine 55 BoNTA 55 AVODART 55 PSMA ADC 55 leukopenia 55 dose limiting toxicities 55 Elotuzumab 55 ER CHOP 55 HSCT 55 5 FU 55 allopurinol 55 unresectable 55 #mg BID [003] 55 alteplase 55 Cyclophosphamide 55 bosutinib 55 comparator PI 55 nonmetastatic prostate cancer 55 nucleoside naive patients 55 multicenter randomized 55 relapsing multiple sclerosis 55 vicriviroc 55 dose colchicine 55 PROSTVAC VF 55 Follicular Lymphoma 55 ALA PDT 55 tipranavir 55 plus 5-FU/LV 55 subcutaneous enoxaparin 55 Exemestane 55 Response Evaluation Criteria 55 rituximab monotherapy 55 prednisone prednisolone plus 55 mg clopidogrel 55 olaparib 55 tanespimycin 55 SUTENT 55 multicenter placebo controlled 55 5 Fluorouracil 55 RoACTEMRA 55 WBRT 55 thalidomide dexamethasone 55 febuxostat 55 micafungin 55 pharmacokinetic interactions 55 tumor shrinkage 55 cancer mCRC 55 Mitoxantrone 55 LT NS# 55 oral prodrug 55 PegIntron 55 oral Hycamtin 55 lipid lowering agents 55 #mg QD [002] 55 mCi m 2 55 grade glioma 55 ceftriaxone 55 teriparatide 55 Virulizin ® 55 Tipranavir 55 isoproterenol 55 tolerability 55 ACZ# 55 valsartan 55 TDF FTC 55 Gefitinib 55 formoterol fumarate 55 leflunomide 55 intratumoral 55 F FDG PET 55 lung metastases 55 Halaven 55 paclitaxel Taxol R 55 budesonide formoterol 55 insulin glulisine 55 anastrozole 55 Interferon alfa 55 MCyR 55 coadministration 55 seropositive patients 55 pazopanib 55 DOXIL ® 55 INTELENCE 55 alicaforsen enema 55 blinded randomized placebo controlled 55 TPV r 55 placebo controlled clinical 55 histological subtype 55 mg/# h 55 CCyR 55 tamoxifen Nolvadex ® 55 oral vancomycin 55 SUVmax 55 CTAP# Capsules 55 erlotinib Tarceva 55 % CI #.#-#.# [003] 55 Neoadjuvant 55 Camptosar ® 55 highly emetogenic 55 nonrandomized 55 metaglidasen 55 peg interferon 55 refractory CTCL 55 Hycamtin 55 tipranavir ritonavir 55 tolterodine ER 55 oxcarbazepine 55 q8h 55 hA# 55 telaprevir dosing 55 nilotinib Tasigna ® 55 regorafenib 55 EndoTAGTM 1 55 Sanofi Aventis Taxotere 55 advanced hepatocellular carcinoma 55 tumor xenograft models 55 pegaptanib 55 COMBIVIR 55 naïve HCV 55 gadobutrol 55 trans retinoic acid 55 papillary renal cell carcinoma 55 squamous 55 dosed orally 55 Hycamtin ® 55 GP IIb IIIa inhibitors 55 intravenous cyclophosphamide 55 Capesaris 55 bisoprolol 55 REYATAZ R 55 primary hypercholesterolemia 55 Monotherapy 55 oxycodone IR 55 QD dosing 55 serum clusterin levels 55 achieved CCyR 55 CYT# potent vascular disrupting 55 histologically confirmed 55 Kaplan Meier estimate 55 eribulin 55 oral ridaforolimus 55 Cytoxan 55 μg ml 55 MADRS score 55 APOPTONE 55 raltegravir 55 mg q#h 55 log# copies mL 55 REVLIMID lenalidomide 55 taxane refractory 55 thromboembolic events 55 ketorolac 55 5 fluorouracil leucovorin 55 lymph node involvement 55 Pred Forte 55 binary restenosis 55 Retreatment 55 Helicobacter pylori eradication 55 CBLC# 55 relapsed SCLC 55 malignancy HCM 55 administered subcutaneously 55 leucopenia 55 aspirin heparin 55 deferiprone 55 hypophosphatemia

Back to home page